4/A: Revolution Medicines Director Sushil Patel Amends SEC Filing to Correct Stock Option and RSU Award Amounts

Sushil Patel, a director at Revolution Medicines, filed an amended SEC Form 4 to correct previously reported amounts for restricted stock units and stock options granted on June 20, 2024.

Summary

• Sushil Patel, a director at Revolution Medicines, filed an amendment to a previous SEC Form 4 filing.
• The amendment corrects the amounts reported for restricted stock units (RSUs) and stock options granted to Patel on June 20, 2024.
• The original filing on June 24, 2024, inadvertently reported incorrect amounts.
• The corrected filing shows Patel acquired 4,248 shares of common stock and now beneficially owns 19,948 shares, including 8,623 RSUs.
• Patel also acquired a stock option to buy 15,955 shares of common stock at an exercise price of $37.54, which vests on the earlier of June 20, 2025, or immediately prior to the company's annual meeting of stockholders following the grant date.

Sentiment

Score: 7

Explanation: The document is a routine correction of a regulatory filing. While the initial error might raise a slight concern, the prompt amendment suggests good corporate governance. Overall, the sentiment is neutral to slightly positive.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biopharmaceutical industry.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding executive compensation.

Key Dates